LF
RPRX icon

Lansforsakringar Fondforvaltning’s Royalty Pharma RPRX Stock Holding History

Lansforsakringar Fondforvaltning’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.03M Sell
161,125
-1,664
-1% -$86.6K 0.04% 323
2026
Q1 		$7.81M Buy
162,789
+13,910
+9% +$609K 0.04% 319
2025
Q4 		$5.75M Buy
148,879
+5,347
+4% +$204K 0.03% 379
2025
Q3 		$5.06M Sell
143,532
-8,541
-6% -$309K 0.03% 401
2025
Q2 		$5.48M Buy
152,073
+1,515
+1% +$50.2K 0.03% 376
2025
Q1 		$4.69M Buy
150,558
+214
+0.1% +$6.78K 0.03% 401
2024
Q4 		$3.84M Buy
+150,344
New +$3.99M 0.02% 441

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Lansforsakringar Fondforvaltning's RPRX Position: Q2 2026 in Review

Lansforsakringar Fondforvaltning reduced its Royalty Pharma (RPRX) stake by 1% in Q2 2026, selling an estimated $86.6K and leaving 161,125 shares worth $9.03M. The position accounts for 0.04% of the portfolio, ranked #323.

Lansforsakringar Fondforvaltning first reported a position in RPRX in Q4 2024 and has held it in 7 quarters since. 647 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Lansforsakringar Fondforvaltning held 161,125 shares of Royalty Pharma worth $9.03M as of Q2 2026.
  • Lansforsakringar Fondforvaltning sold 1,664 Royalty Pharma shares in Q2 2026, an estimated $86.6K.
  • Royalty Pharma made up 0.04% of Lansforsakringar Fondforvaltning's portfolio in Q2 2026, its #323 holding.
  • Lansforsakringar Fondforvaltning first reported a position in Royalty Pharma in Q4 2024 and has held it in 7 quarters since.
  • 647 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Lansforsakringar Fondforvaltning's 13F filing for Q2 2026, filed 13 Aug 2026.